David Amsellem
Stock Analyst at Piper Sandler
(4.25)
# 263
Out of 4,810 analysts
144
Total ratings
53.04%
Success rate
11.91%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CORT Corcept Therapeutics | Maintains: Overweight | $128 → $131 | $67.43 | +94.28% | 7 | Apr 3, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $36 → $32 | $24.42 | +31.04% | 8 | Mar 21, 2025 | |
| OPTN OptiNose | Downgrades: Neutral | $15 → $9 | $9.10 | -1.10% | 3 | Mar 21, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Neutral | $3 → $4 | $4.16 | -3.85% | 5 | Mar 7, 2025 | |
| INDV Indivior | Maintains: Overweight | $16 → $13 | $9.44 | +37.71% | 5 | Mar 6, 2025 | |
| VTRS Viatris | Reiterates: Neutral | $14 → $10 | $7.63 | +31.06% | 7 | Mar 5, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $163 → $176 | $101.75 | +72.97% | 13 | Feb 26, 2025 | |
| AMGN Amgen | Maintains: Overweight | $310 → $329 | $293.92 | +11.94% | 2 | Feb 10, 2025 | |
| COLL Collegium Pharmaceutical | Maintains: Neutral | $37 → $36 | $26.73 | +34.68% | 7 | Feb 4, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $23 → $30 | $13.60 | +120.59% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $7.73 | +68.18% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $9 | $7.40 | +21.62% | 1 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $94.89 | +68.62% | 9 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $7.21 | +52.57% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $27.54 | +34.35% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $68.72 | -1.05% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $31.60 | +13.92% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $4.34 | -30.88% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $24.97 | +68.20% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $11.30 | +112.39% | 5 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $2.52 | +296.83% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $0.65 | +3,141.24% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $103.53 | +9.15% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $144 → $12 | $5.55 | +116.22% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $29.53 | +42.23% | 3 | Oct 16, 2023 |
Corcept Therapeutics
Apr 3, 2025
Maintains: Overweight
Price Target: $128 → $131
Current: $67.43
Upside: +94.28%
Amphastar Pharmaceuticals
Mar 21, 2025
Maintains: Neutral
Price Target: $36 → $32
Current: $24.42
Upside: +31.04%
OptiNose
Mar 21, 2025
Downgrades: Neutral
Price Target: $15 → $9
Current: $9.10
Upside: -1.10%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $4.16
Upside: -3.85%
Indivior
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $9.44
Upside: +37.71%
Viatris
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $7.63
Upside: +31.06%
Jazz Pharmaceuticals
Feb 26, 2025
Reiterates: Overweight
Price Target: $163 → $176
Current: $101.75
Upside: +72.97%
Amgen
Feb 10, 2025
Maintains: Overweight
Price Target: $310 → $329
Current: $293.92
Upside: +11.94%
Collegium Pharmaceutical
Feb 4, 2025
Maintains: Neutral
Price Target: $37 → $36
Current: $26.73
Upside: +34.68%
Teva Pharmaceutical Industries
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $13.60
Upside: +120.59%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $7.73
Upside: +68.18%
Jan 2, 2025
Maintains: Overweight
Price Target: $26 → $9
Current: $7.40
Upside: +21.62%
Dec 23, 2024
Reiterates: Overweight
Price Target: $160
Current: $94.89
Upside: +68.62%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $7.21
Upside: +52.57%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $27.54
Upside: +34.35%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $68.72
Upside: -1.05%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $31.60
Upside: +13.92%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $4.34
Upside: -30.88%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $24.97
Upside: +68.20%
Apr 29, 2024
Maintains: Overweight
Price Target: $22 → $24
Current: $11.30
Upside: +112.39%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $2.52
Upside: +296.83%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $0.65
Upside: +3,141.24%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $103.53
Upside: +9.15%
Nov 14, 2023
Downgrades: Neutral
Price Target: $144 → $12
Current: $5.55
Upside: +116.22%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $29.53
Upside: +42.23%